Fig. 5
The antitumor therapeutic efficacy of SNP-Fe@MNs in vitro. a Relative cell viability of B16 cells from the Control, SCMC@MNs, SNP-Fe@MNs-UV(-), Fe@MNs, and SNP@MNs groups. b Relative cell viability of B16 cells from the Control, SCMC@MNs, UV-cell, UV-SNP-Fe@MNs-NIR(−)-NO(+), UV-SNP-Fe@MNs-NIR(+)-NO(−), and UV-SNP-Fe@MNs-NIR(+)-NO(+) groups. c CLSM images of B16 cells stained via the Calcein-AM/PI Kit from the Control, SNP-Fe@MNs-NIR(+)-NO(−), SNP-Fe@MNs-NIR(−)-NO(+), SNP-Fe@MNs-NIR(+)-NO(+) groups. d The relative proportion of living and dead cells. e–i Protein levels of Caspase-3 (f), HSP-70 (g), HSP-90 (h), and AKT (i) after treated by MNs (n = 6. *P < 0.05; **P < 0.01; ***P < 0.0001)